



**18th  
ICML**

International  
Conference  
on Malignant  
Lymphoma  
**Lugano**

**17-21  
June  
2025**

Scan  
the QR code  
to download the  
18-ICML App



# Programme Book

The programme is subject to changes,  
for updates visit [www.icml.ch](http://www.icml.ch)

© Keystone – ATS / TI-Press / Massimo Piccoli

Organised by In cooperation with




**AACR** American Association  
for Cancer Research\*



**ESMO** GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE





Printed by courtesy of AstraZeneca



**ICML wi-fi**

Complimentary internet wi-fi access is available for Conference delegates throughout the 18-ICML locations, thanks to the support of AstraZeneca.

To access wi-fi, please use the following information:  
network name (SSID): ICML2025  
password (PSK): Lugano2025  
or scan the below QRcode:



Please note that wi-fi connection speed and performance depend on number of simultaneous accesses.

**INDEX**

Acknowledgements	2
General information	6
18-ICML locations, floorplans, opening days and hours	8
- Palazzo dei Congressi	
- Marquee Parco Ciani	
- Villa Ciani	
- Asilo Ciani	
- Cinema Corso	
- Auditorium, West Campus USI	
- Polivalente room, East Campus USI	
Programme at a glance	20
Conference schedule	25
Transport information	68

SAVE  
THE  
DATE

15-19  
June  
2027

19th  
ICML  
International  
Conference  
on Malignant  
Lymphoma  
Lugano

# ACKNOWLEDGEMENTS

## International Conference on Malignant Lymphoma (ICML) and Foundation for the Institute of Oncology Research (IOR) President

Franco Cavalli, Bellinzona, CH

## Organising Committee Chairman

Francesco Bertoni, Bellinzona, CH

## Organising Committee

Helmut Beltraminelli

Francesco Ceppi

Adalgisa Condoluci

Maria Cristina Piroso

Davide Robbiani

Davide Rossi

Margaret A. Shipp, Boston, MA,

US - Representative of American Association for Cancer Research (AACR)

Anastasios Stathis

Georg Stüssi

Doris Vola, Lugano, CH - Representative of

European Society for Medical Oncology (ESMO)

Emanuele Zucca

## 18-ICML Scientific Advisory Board

Ranjana H. Advani, Palo Alto, CA, US

James O. Armitage, Omaha, NE, US – Chairman

Elias Campo, Barcelona, ES

Bruce D. Cheson, Bethesda, MD, US

Riccardo Dalla-Favera, New York, NY, US

Matthew S. Davids, Boston, MA, US

Stephan Dirnhofer, Basel, CH

Martin Dreyling, Munich, DE

Manuela Eicher, Lausanne, CH

Andrew M. Evens, New Brunswick, NJ, US

Jonathan W. Friedberg, Rochester, NY, US

David C. Hodgson, Toronto, ON, CA

Peter W.M. Johnson, Southampton, UK

Brad S. Kahl, St. Louis, MO, US

Won Seog Kim, Seoul, KR

T. Andrew Lister, London, UK

Stefano Luminari, Reggio Emilia, IT

Ari M. Melnick, New York, NY, US

Bertrand Nadel, Marseilles, FR

Urban Novak, Bern, CH

Grzegorz S. Nowakowski, Rochester, MN, US

Koichi Ohshima, Kurume, JP

Astrid Pavlovsky, Buenos Aires, AR

Leticia Quintanilla de Fend, Tübingen, DE

Gilles Salles, New York, NY, US

Kerry J. Savage, Vancouver, BC, CA

John F. Seymour, Melbourne, AU

Sonali M. Smith, Chicago, IL, US

Lena Specht, Copenhagen, DK

Catherine Thieblemont, Paris, FR

Marek Trnieny, Prague, CZ

Wilhelm Wössmann, Hamburg, DE

Thorsten Zenz, Zurich, CH

Weili Zhao, Shanghai, CN

Pier Luigi Zinzani, Bologna, IT

The Organising Committee is proud to cooperate with the following **international associations, societies and groups**. Their collaboration in jointly defining several of the sessions and workshops is essential to the achievement of ICML objectives and learning outcomes.

American Association for Cancer Research - AACR

European Oncology Nursing Society - EONS

European Society for Medical Oncology - ESMO

European School of Oncology Foundation - ESOF

European Society for Paediatric Oncology Nursing

Group - SIOPE

Haematology Nurses & Healthcare Professionals

Group - HNHCP

International Lymphoma Radiation Oncology

Group - ILROG

Swiss Oncology Nursing Society - OPS/SOS

Union for China Lymphoma Investigators - UCLI

Lymphoma Canine Network.

The Organising Committee also wishes to thank the following colleagues and friends for their valuable support as **reviewers**: with their collaboration and professional commitment, more than 1000 submitted abstracts have been evaluated, a new record (over 200 more than in 2023)!

Ranjana H. Advani, Palo Alto, CA, US

Erik Aerts, Zurich, CH

Stephen M. Ansell, Rochester, MN, US

James O. Armitage, Omaha, NE, US

Tracy T. Batchelor, Boston, MA, US

Christian Buske, Ulm, DE

Vincent Camus, Rouen, FR

Francesco Ceppi, Lausanne, CH

Luca Ceriani, Bellinzona, CH

Bruce D. Cheson, Bethesda, MD, US

Carlos Chiatton, Sao Paulo, BR

Sara Colomer-Lahiguera, Lausanne, CH

Matthew S. Davids, Boston, MA, US

Andy Davies, Southampton, UK

Martin Dreyling, Munich, DE

Manuela Eicher, Lausanne, CH

Barbara F. Eichhorst, Cologne, DE

Andrew M. Evens, New Brunswick, NJ, US

Andrés J.M. Ferreri, Milan, IT

Christopher R. Flowers, Atlanta, GA, US

Christopher P. Fox, Nottingham, UK

Jonathan W. Friedberg, Rochester, NY, US

Francesca Gay, Turin, IT

Berhard Gerber, Bellinzona, CH

Matthias Hellberg-Naegele, St. Gallen, CH

Alex F. Herrera, Duarte, CA, US

David C. Hodgson, Toronto ON, CA

Martin Hutchings, Copenhagen, DK

Gloria Iacoboni, Barcelona, ES



# ACKNOWLEDGEMENTS

Won Seog Kim, Seoul, KR  
John Kuruvilla, Toronto ON, CA  
Steven Le Gouill, Paris, FR  
Georg Lenz, Münster, DE  
Stefano Luminari, Reggio Emilia, IT  
Maurizio Martelli, Rome, IT  
Patrizia Mondello, Rochester, MN, US  
Franck Morschhauser, Lille, FR  
Bertrand Nadel, Marseilles, FR  
Urban Novak, Bern, CH  
Grzegorz S. Nowakowski, Rochester, MN, US  
Ariela Noy, New York, NY, US  
Christiane Pott, Kiel, DE  
Barbara Pro, New York, US  
Leticia Quintanilla-Martinez, Tübingen, DE  
Vincent Ribrag, Villejuif, FR  
Umberto Ricardi, Turin, IT  
Mark Roschewski, Bethesda, MD, US  
Gilles Salles, New York, NY, US  
Elisabeth Schorb, Freiburg, DE  
David Scott, Vancouver BC, CA  
Laurie H. Sehn, Vancouver BC, CA  
John F. Seymour, Melbourne VIC, AU  
Margaret A. Shipp, Boston, MA, US  
Sonali M. Smith, Chicago, IL, US  
Yuqin Song, Beijing, CN  
Lena Specht, Copenhagen, DK  
Catherine Thieblemont, Paris, FR  
Hervé Tilly, Rouen, FR  
Steven P. Treon, Boston, MA, US  
Marek Trneny, Prague, CZ  
Bastian von Tresckow, Essen, DE  
Michael Wang, Houston, TX, US  
Jason Westin, Houston, TX, US  
Wilhelm Wössmann, Hamburg, DE  
Pier Luigi Zinzani, Bologna, IT

The Organising Committee would like to express their sincere gratitude to the **industry partners** who continue to support the Conference. Their unrestricted support is essential to the dissemination of the programme to the worldwide community engaged in the study and treatment of lymphoid neoplasms:

AbbVie  
Acrotech  
Allogene Therapeutics  
Arvinas  
AstraZeneca  
BeOne  
Bristol Myers Squibb  
CRISPR Therapeutics  
Eli Lilly and Company  
Follicular Lymphoma Foundation  
Galapagos  
Genexpath  
Genmab  
Gilead & Kite  
Ideogen  
Incyte  
Johnson & Johnson  
Miltenyi Biomedicine  
MSD  
Nurix Therapeutics, Inc.  
Pierre Fabre  
Regeneron  
Roche  
Secura Bio  
SERB Pharmaceuticals  
Sobi  
Stratpharma  
Takeda  
Wecare  
(updated in May 2025)

Lastly, the Organising Committee would like to express their sincere gratitude to the following **institutional partners** for their precious support, essential to the organisation of this Conference:

City of Lugano  
Lugano Region - Ente Turistico del Luganese  
Ticino Tourism  
Università della Svizzera Italiana - USI

## Conference secretariat

Cristiana Brentan, Federica Cariglia,  
Laura Di Petto, Orietta Lugli, Stéphanie Pedrioli,  
Chiara Saporiti  
Damian Stauffer – trainee  
Foundation for the Institute of Oncology  
Research (IOR)  
Via Vela 6, CH-6500 Bellinzona

## GENERAL INFORMATION

Participants in the 18-ICML will be able to download the **certificate of attendance** from their dashboard on MyICML platform, after completing the evaluation form.  
The ICML is not accredited with European CME.

### 18-ICML Educational Book

Articles of the Educational Symposia and Meet the Professor sessions are included in the 18-ICML Educational Book, supplement to “Hematological Oncology” and published by Wiley.  
The supplement is available online at the ICML official website ([www.icml.ch](http://www.icml.ch)) and at the Wiley Online Library website ([onlinelibrary.wiley.com](http://onlinelibrary.wiley.com)).

### 18-ICML Abstract Book

All selected abstracts are included in the 18-ICML Abstract Book, published by Wiley and available online at the ICML website ([www.icml.ch](http://www.icml.ch)) and at the Wiley Online Library website ([onlinelibrary.wiley.com](http://onlinelibrary.wiley.com)).

### 18-ICML Official App

We are pleased to introduce a brand-new tool for this year's Conference: our official mobile App. Developed to support and enhance the onsite experience, the App offers easy access to the programme, real-time updates and venue navigation tools.  
Onsite participants are encouraged to download it to make the most of their time at the event.

### 18-ICML Travel Grants

A limited number of travel grants are provided to young investigators (less than 35 years old), whose abstract has been accepted for an oral presentation.

The selection was made based on the abstract evaluation results.  
Congratulations!


Nikhil P. Mankuzhy, New York, NY, US  
Alexandra D. Dreyfuss, New York, NY, US  
Rebecca Wurm-Kuczera, Berlin, DE  
Maria C. Ferrandez Ferrandez, Amsterdam, NL  
Patrizia Mondello, Rochester, MN, US  
Mouhamad Khouja, Kiel, DE  
Riccardo Moia, Novara, IT  
Jan-Michel Heger, Cologne, DE  
Daniel Filip, Brno, CZ  
Justin Ferdinandus, Cologne, DE  
Patrick C. Johnson, Boston, MA, US  
Oscar Atkins, London, UK  
Daniel Reef, Chapel Hill, NC, US

### Scientific collaborations

The 18-ICML programme will be part of the Certificate of Advanced Studies in Lymphoma, a 15-month ECTS programme developed by the European School of Oncology – ESO.  
The aim of the Certificate of Advanced Studies is to provide a curriculum of studies to advance the knowledge and science in the management of lymphoma patients.  
Further information can be obtained by visiting [www.eso.net](http://www.eso.net)  
The 18-ICML is labelled as a European School of Oncology Recommended Event.

18-ICML is supported by the European Society for Medical Oncology - ESMO and is accredited with 25 ESMO-MORA cat. 1 points.

## Download the 18-ICML official APP



Scan the QR code and make the most of your Conference experience



# 18-ICML LOCATIONS, FLOORPLANS, OPENING DAYS AND HOURS

1

**Palazzo dei Congressi**  
Piazza Indipendenza 4

2

**Marquee**  
Parco Ciani

3

**Villa Ciani**  
Parco Ciani

4

**Asilo Ciani**  
Via Carlo Cattaneo 5

5

**Cinema Corso**  
Via G. B. Pioda 4

6

**Auditorium**  
**West Campus USI**  
Via G. Buffi 13

7

**Polivalente room**  
**East Campus USI**  
Via La Santa 1

8

**Campo Marzio Parking**  
Via Campo Marzio



**Lugano Centro**  
TPL line bus stop





**Hospital EOC Ospedale**  
**Regionale di Lugano**  
– Italiano



**Parking**



Scan the QR code  
to get the 18-ICML map  
on Google Maps



# PALAZZO DEI CONGRESSI

Piazza Indipendenza 4, Lugano

Scientific and industry programmes, registration and industry desks, meeting rooms C2, C3, D, E and H.  
Services: buvette, wi-fi, water dispensers, cloakroom, restrooms, lockers (level -1)

## Registration and Industry programme desks

Phone: +41 58 866 66 68

Monday, 16 June	08:00 – 19:30
from Tuesday, 17 to Friday, 20 June	07:00 – 19:30
Saturday, 21 June	07:00 – 13:00 (cloakroom 18:00)

## Speaker preview center, room A balcony

Monday, 16 June	12:00 – 18:00
from Tuesday, 17 to Friday, 20 June	07:00 – 19:00
Saturday, 21 June	07:00 – 12:00

## Transport Info desk

Monday, 16 June	08:00 – 19:30
from Tuesday, 17 to Friday, 20 June	07:00 – 19:30
Saturday, 21 June	07:00 – 13:00


Amiconi Consulting SA info desk  
Information on hotel accommodation and private transfer services

Phone: +41 58 866 66 78


The following scientific associations, patient organisation and agencies will be present in front of room A from Wednesday, 18 to Friday, 20 from 09:00 to 17:00:

5P Health Care Solutions  
AACR – American Association for Cancer Research  
ESO - European School of Oncology  
ESMO – European Society for Medical Oncology  
Follicular Lymphoma Foundation  
IELSG – International Extranodal Lymphoma Study Group  
Lymphoma Coalition  
HNHCP - Haematology Nurses & Healthcare Professionals Group

## Ground floor



## First floor





# MARQUEE PARCO CIANI

Overflow and poster areas, industry exhibition, social moments, coffee break and lunch area.  
Services: wi-fi, water dispensers, restrooms

## Opening days and hours

Tuesday, 17 June	14:00 – 18:00
from Wednesday, 18 to Friday, 20 June	09:00 – 18:00

## Coffee breaks

Wednesday, 18 June	10:15 – 10:35 15:15 – 15:45
Thursday, 19 June	10:30 – 11:00 15:30 – 15:45
Friday, 20 June	10:30 – 11:00

## Poster presentations

Posters are on display throughout the Conference during the Marquee Parco Ciani opening hours.  
Presenters are kindly asked to be available by their poster for Q&A with attendees from 12:30 to 13:00, on:

- Thursday, 19 June: odd-numbered posters
- Friday, 20 June: even-numbered posters

## GREEN PROJECT

18-ICML is committed to being a climate conscious event. To partially compensate for the carbon emissions of our Conference, as of 2019 our Organising Committee has been supporting projects aiming at combating climate change, protecting biodiversity and promoting sustainable technology. In particular, 18-ICML will support the upgrade of the photovoltaic plant at the Centre for Molecular Immunology (CIM), located in Havana, Cuba.

*CIM is a research institute that focuses on the research and production of new biopharmaceuticals for the treatment of cancer and other non-communicable diseases. The Centre's basic research projects focus on cancer immunotherapy, and in particular the development of molecular vaccines.*

The first stage of the project began in 2024 to supplement the existing plant on the Centre's roofs with new solar panels, capable of generating 60 kWp of power, which will be available to the research laboratories.





# VILLA CIANI

Meeting rooms 1 – 10  
Sit&Meet area  
Services: wi-fi, water dispensers, lift, restrooms (- 1 level)

## Opening days and hours

from Monday, 16 to Friday , 20 June 08:00 - 20:00

## Ground floor

Meeting room 1 and 1bis	Bristol Myers Squibb
Meeting room 2	Eli Lilly and Company
Meeting room 3	Bristol Myers Squibb
Meeting room 4	AstraZeneca
Meeting room 5	AstraZeneca
Meeting room 6 and 6bis	Genmab


## First floor

Meeting room 7	Roche
Meeting room 8	Incyte


## Second floor

Meeting room 9	Regeneron
Meeting room 10	Regeneron


## Ground floor



## First floor



## Second floor




# ASILO CIANI AND BACKYARD

Meeting rooms 11 – 17, TINY SPACES 18 - 24  
Sit&Meet area  
Services: wi-fi, water dispensers, restrooms

## Opening days and hours

from Monday, 16 to Friday, 20 June	07:00 - 21:00
Saturday 21	07:00 - 17:00 / TINY SPACES close at 15:00

Meeting room 11	BeOne
Meeting room 12	BeOne
Meeting room 13	Gilead&Kite
Meeting room 14	Gilead&Kite
Meeting room 15	Takeda
Meeting room 16	Takeda
Meeting room 17	AbbVie
TINY SPACE 18	Eli Lilly and Company
TINY SPACE 19	Eli Lilly and Company
TINY SPACE 20	Sobi
TINY SPACE 21	Arvinas
TINY SPACE 22	Roche
TINY SPACE 23	Nurix Therapeutics
TINY SPACE 24	Galapagos



## CINEMA CORSO

Via G. B. Pioda 4

Parallel scientific sessions

Room A overflow area

Services: wi-fi, water dispensers and restrooms

## AUDITORIUM, WEST CAMPUS USI

Via G. Buffi 13

Parallel scientific sessions

Overflow area

Industry programme – satellite symposia

Services: wi-fi, water dispensers and restrooms

## POLIVALENTE ROOM, EAST CAMPUS USI

Via La Santa 1

Parallel scientific sessions

Overflow area

Services: wi-fi, water dispensers and restrooms

### Certifications for a concrete commitment


Lugano Convention & Exhibition and all its locations are certified ISO 20121, the international standard for sustainable event management, recognised by Swiss LiveCom Association EXPO EVENT and Acting Responsibly. In addition, we are part of the Swisstainable programme, with the highest level of certification (Level III - Leading), confirming our commitment to a more sustainable future in the conference industry.




### An eco-sustainable venue

The energy needs of the Palazzo dei Congressi are entirely covered by sustainable products: Biogas Basic (10% biogas) and renewable electricity Tiacqua. Both carriers are supplied by the Lugano Industrial Companies (AIL SA). Biogas is a renewable energy source; it is formed by the fermentation of organic waste, such as vegetable waste or sewage sludge. Tiacqua is an energy product from Ticino's hydroelectric power stations; it is the result of collaboration between Enerti, AET and Ticino's distributors, including AIL SA. A natural choice!


### Cinema Corso



### Auditorium, west campus USI



### Polivalente room, east campus USI





## PROGRAMME AT A GLANCE

[illegible]

Wednesday, 18 June					
	Room A, Palazzo dei Congressi	Room B, Palazzo dei Congressi	Cinema Corso	Auditorium, West Campus USI	Polivalente Room, East Campus USI
0830 - 0915	<b>Meet the Professor</b> A.M. EVENS	<b>Meet the Professor</b> G.S. NOWAKOWSKI	<b>Meet the Professor</b> F. GAY	<b>Meet the Professor</b> S.M. SMITH	<b>Meet the Professor</b> J. OKOSUN
0930 - 1015	<b>Meet the Professor</b> E. CAMPO and P. BORCHMANN	<b>Meet the Professor</b> M.S. DAVIDS	<b>Meet the Professor</b> F. GAY	<b>Meet the Professor</b> G. IACOBONI	<b>Meet the Professor</b> S.P. TREON
1035 - 1200	<b>Educational symposium A</b> MANTLE CELL LYMPHOMA S. Ferrero, M. Dreyling, E. Giné Soca	<b>Educational symposium B</b> CLONAL PRECURSORS M. Manz, C. Dearden, P. Ghia, A. Dispenzieri	Broadcasting of <b>Educational symposium A</b>	Broadcasting of <b>Educational symposium B</b>	
Lunch time & Poster viewing					
1300 - 1355	<b>Opening</b> of the Conference <b>H. Kaplan Memorial Lecture and ICML Prize</b>	Broadcasting of <b>Opening of the Conference, H. Kaplan Memorial Lecture and ICML Prize</b> B.D. Cheson - E.S. Jaffe Laudatio: F. Cavalli			
1400 - 1515	<b>Plenary session</b>	Broadcasting of <b>Plenary session</b>			
1545 - 1645	<b>AACR-ICML Joint session</b> THE ROLE OF ARTIFICIAL INTELLIGENCE IN ONCOLOGY	Broadcasting of <b>AACR-ICML Joint session</b>			
1700 - 1800	<b>Focus on</b> FOLLICULAR LYMPHOMA	<b>Focus on</b> NEW CELLULAR THERAPIES	<b>Focus on</b> ONGOING TRIALS	<b>Focus on</b> RADIATION THERAPY	<b>Focus on</b> EXPERIMENTAL THERAPEUTICS
1900 - 2030	<b>ABBVIE</b> Industry satellite symposium	<b>TAKEDA</b> Industry satellite symposium			

Thursday, 19 June					
	Room A, Palazzo dei Congressi	Room B*, Palazzo dei Congressi	Cinema Corso	Auditorium, West Campus USI	Polivalente Room, East Campus USI
		* broadcast in Marquee Parco Ciani			
08:15 - 09:00	<b>Meet the Professor</b> S. DIRNHOFFER and A. DISPENZIERI	<b>Meet the Professor</b> G.S. NOWAKOWSKI	<b>Meet the Professor</b> W.S. KIM	<b>Meet the Professor</b> S.P. TREON	<b>Meet the Professor</b> S.M. SMITH
09:15 - 10:30	<b>Challenging Cases Discussion</b> AGGRESSIVE B-CELL LYMPHOMAS	<b>Session 1</b> IMAGING AND RADIOMICS	<b>Challenging Cases Discussion</b> T-CELL LYMPHOMA	<b>Challenging Cases Discussion</b> PAEDIATRIC LYMPHOMAS	<b>Session 2</b> LYMPHOMA EPIGENETICS
11:00 - 12:00	<b>Session 3</b> HODGKIN LYMPHOMA FROM CHILDREN TO ADULTS	Broadcasting of <b>Session 3</b>			<b>Focus on</b> CROSS-CUTTING TOPICS
Lunch time & Poster viewing					
13:00 - 13:45	<b>G. Bonadonna Memorial Lecture</b>	Broadcasting of <b>G. Bonadonna Memorial Lecture</b> D. Scott Laudatio: R. Dalla-Favera			
14:00 - 15:30	<b>Session 4</b> FOLLICULAR LYMPHOMA	Broadcasting of <b>Session 4</b>		14:00-16:35 <b>Session 5</b> PEDIATRIC LYMPHOMAS	<b>Session 6</b> LIQUID BIOPSY FOR RESPONSE ASSESSMENT
15:45 - 17:00	<b>Session 7</b> MANTLE CELL LYMPHOMA	<b>Session 8</b> MARGINAL ZONE AND LYMPHOPLASMACYTIC LYMPHOMAS	Broadcasting of <b>Session 7</b>		<b>Session 9</b> GENOMICS AND CLONAL HEMATOPOIESIS
17:15 - 18:15	<b>Focus on</b> HODGKIN LYMPHOMA	<b>Focus on</b> MANTLE CELL LYMPHOMA	<b>Focus on</b> CAR T-CELLS OUTCOMES	<b>Focus on</b> EARLY CLINICAL TRIALS	<b>Focus on</b> LIQUID BIOPSY
19:00 - 20:30	<b>ALLOGENE THERAPEUTICS</b> Industry satellite symposium	<b>ABBVIE</b> Industry satellite symposium		<b>PIERRE FABRE</b> Industry satellite symposium	in Room E <b>FOLLICULAR LYMPHOMA FOUNDATION</b> Satellite symposium

Friday, 20 June					
	Room A, Palazzo dei Congressi	Room B*, Palazzo dei Congressi	Cinema Corso	Auditorium, West Campus USI	Polivalente Room, East Campus USI
		* broadcast in Marquee Parco Ciani			
08:15 - 09:00	Meet the Professor G. IACOBONI	Meet the Professor W.S. KIM	Meet the Professor W. BARCELLINI	Meet the Professor A.M. EVENS	Meet the Professor J. OKOSUN
09:15 - 10:30	Challenging Cases Discussion INDOLENT NHLs and CLL	Session 10 NK/T-CELL LYMPHOMA	Challenging Cases Discussion DIFFICULT PATHOLOGICAL CASES	09:15 - 12:00 International Lymphoma Radiation Oncology Group (ILROG) Workshop "Low doses, few fractions, and new indications for radiation therapy in haematological malignancies" open to all 18-ICML attendees	Session 11 MECHANISMS OF RESISTANCE IN LYMPHOMAS
11:00 - 12:00	Session 12 CHRONIC LYMPHOCYTIC LEUKEMIA	Focus on DLBCL in the Elderly	Broadcasting of Session 12		Broadcasting of Session 12
Lunch time & Poster viewing					
13:00 - 13:45	J. Ultmann Memorial Lecture	Broadcasting of J. Ultmann Memorial Lecture E. Zucca Laudatio: T.A. Lister			
14:00 - 15:30	Session 13 AGGRESSIVE B-CELL LYMPHOMAS	Session 14 BIOLOGY of FOLLICULAR LYMPHOMA	Broadcasting of Session 13	14:00-17:00  Session 15 ONCOLOGY NURSING	14:30 - 17:00  UCLI-ICML joint session LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE
	15:45-16:00 Closed Workshop Report	15:45-16:00 Broadcasting of Closed Workshop Report			
16:00-17:00	Session 16 LATE BREAKING ABSTRACTS	Broadcasting of Session 16			
17:00-17:45 Farewell Aperitif					
17:45 - 18:45	THE BIG DEBATE organised by IOR Foundation, supported by multiple sponsors				
19:00 - 21:00			ESMO-ICML Special event "Burkitt" (documentary and debate)		

# CONFERENCE SCHEDULE (updated on 30 May)

## TUESDAY, 17 JUNE

10:00 – 16:30 **Polivalente room, East Campus USI** **CLOSED WORKSHOP (in-person event - by invitation only)**  
**GENETICS OF DIFFUSE LARGE B CELL LYMPHOMA: TOWARD IMPROVED DIAGNOSIS, OUTCOME PREDICTION AND THERAPEUTIC TARGETING**  
 Co-chairs: Francesco Bertoni, Bellinzona, CH, Franco Cavalli, Bellinzona, CH and Riccardo Dalla-Favera, New York, NY, US  
*Organised with the support of:*  
*American Association for Cancer Research – AACR*  
*European School of Oncology Foundation - ESOF*  
*European Society for Medical Oncology - ESMO*

### 11:30 – 13:00 **4 parallel satellite symposia**

**Room A** Eli Lilly and Company  
**Optimizing Treatment Pathways and Patient Care in Relapsed/Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia**  
 Chair: Nirav Shah, Milwaukee, WI, US

**Room B1** Gilead & Kite  
**Advancing the Frontiers of Curative Potential with CAR T**  
 Chair: Claire Roddie, London, UK

**Room B2** Incyte  
**Follicular lymphoma treatment approach: balancing efficacy and toxicity**  
 Chair: Christian Buske, Ulm, DE

**Auditorium, West Campus USI** Regeneron  
**Transformative Advances in Lymphoma: Enhancing Patient Care**

### 14:00 – 15:30 **4 parallel satellite symposia**

**Room A** Roche  
**Deciphering treatment in DLBCL: Choosing the right therapy for the right patient now and beyond**  
 Chair: Wendy Osborne, Newcastle upon Tyne, UK

Saturday, 21 June

Room A,  
Palazzo dei Congressi

Room B,  
Palazzo dei Congressi

Session 17  
CNS LYMPHOMAS

Session 18  
NEW DRUGS

Focus on  
BIOLOGY AND THERAPY OF  
T-CELL LYMPHOMAS

18-ICML HIGHLIGHTS "Take Home Messages"

Broadcasting of 18-ICML HIGHLIGHTS

11:15 - 11:30 **Closure and Farewell**

Broadcasting of **Closure and Farewell**

VII INTERNATIONAL WORKSHOP  
ON CANINE LYMPHOMA

"What lies ahead in lymphoma canine therapy?"

organised by the European  
Canine Lymphoma Network

open to all 18-ICML attendees



	<b>Room B1</b>	Symposium organised by PeerView Hematology-Oncology, supported by AstraZeneca <b>The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations</b> Chair: Stephan Stilgenbauer, Ulm, DE
	<b>Room B2</b>	BeOne <b>BTK targeting across lymphomas: The key to effective treatment today and tomorrow</b>
	<b>Auditorium, West Campus USI</b>	MSD <b>Transforming Care: The Role of Novel Agents in Diffuse Large B-Cell Lymphoma (DLBCL) Management</b> Chair: Marco Ladetto, Alessandria, IT
14:00 – 17:00	<b>Cinema Corso</b>	<b>LYMPHOMA RADIOTHERAPY WORKSHOP</b> <b>NEW FRONTIERS IN RADIATION THERAPY OF HAEMATOLOGICAL MALIGNANCIES - AUGMENTING THE EFFECT OF SYSTEMIC THERAPY</b> <i>Organised in collaboration with the International Lymphoma Radiation Oncology Group - ILROG</i>
14:00–15:30		<b>PART 1: RADIATION THERAPY AND CAR-T-CELL THERAPY, AN UPDATE</b> Chairs: David C. Hodgson, Toronto ON, CA and Joachim Yahalom, New York, NY, US
14:00		<b>Bridging, debulking and/or priming, what is/are the mechanisms underlying the effect of radiation therapy in CAR-T-cell therapy?</b> Carl DeSelm, St. Louis, MO, US
14:15		<b>Update on the UK experience (RESTART protocol)</b> Andrea Kuhn, London, UK
14:30		<b>Update on the MD Anderson experience</b> Bouthaina S. Dabaja, Houston, TX, US
14:45		<b>Effective cytoreduction by RT prior to CAR-T salvage in aggressive B cell lymphomas</b> Harper Hubbeling, Philadelphia, PA, US
15:00		<b>Update on the Toronto experience</b> Danielle Rodin, Toronto ON, CA

15:15		<b>ILROG on the Edge: Walking the “Fine Guideline” For RT-CART</b> John Plastaras, Philadelphia, PA, US, on behalf of the consortium
15:30		BREAK
15:45-17:00		<b>PART 2: NEW ASPECTS IN COMBINING SYSTEMIC THERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HAEMATOLOGICAL MALIGNANCIES</b> Chairs: Michael MacManus, Melbourne VIC, AU and Joanna Yang, St. Louis, MO, US
15:45		<b>Managing the partial response – radiation therapy, salvage chemotherapy, CAR-T-cell therapy, or monitoring</b> Andrea Ng, Boston, MA, US
16:00		<b>Indications for radiotherapy in PET-negative advanced DLBCL</b> George Mikhaeel, London, UK
16:15-16:45		<b>GLOBAL PERSPECTIVE – EXTRANODAL NK/T-CELL LYMPHOMA</b>
16:15		<b>Which systemic regimen should be used today?</b> Man Nie, Guangzhou, CN
16:30		<b>Radiation doses and volumes in early stages with modern systemic therapy</b> Shunan Qi, Beijing, CN
16:45-17:00		<b>PANEL DISCUSSION: COMBINING SYSTEMIC THERAPY AND RADIATION THERAPY IN THESE CLINICAL SITUATIONS</b> All speakers
15:30 – 16:15	<b>Marquee Parco Ciani</b>	WELCOME REFRESHMENT
16:30 – 18:00	<b>4 parallel satellite symposia</b>	
	<b>Room A</b>	Bristol Myers Squibb <b>CAR T in Lymphoma: How Can We Do Better?</b>
	<b>Room B1</b>	Roche <b>Bispecific antibodies: Advances in the treatment of relapsed/refractory follicular lymphoma</b> Chair: Laurie Sehn, Vancouver BC, CA

<b>Room B2</b>	Lymphoma Hub, supported by an independent grant from Eli Lilly and Company <b>Customizing therapy for MCL</b> Chair: Gilles Salles, New York, NY, US
<b>Auditorium, West Campus USI</b>	Sobi <b>Treatment sequencing in R/R DLBCL: Dissecting the emerging challenge from bench to bedside</b> Chair: Andrew Davies, Southampton, UK
<b>4 parallel satellite symposia</b>	
<b>Room A</b>	Symposium organised and supported by Janssen Pharmaceutica NV, a Johnson & Johnson Company <b>From first-line to relapse: the changing landscape of treatment decisions for patients with MCL</b>
<b>Room B1</b>	Symposium organised by PeerView Hematology-Oncology, supported by AstraZeneca <b>Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations</b> Chair: Pier Luigi Zinzani, Bologna, IT
<b>Room B2</b>	Bristol Myers Squibb <b>Driving Transformative Change in Lymphoma: Novel Targets, Innovative Mechanisms, and Evolving Management Strategies</b>
<b>Auditorium, West Campus USI</b>	Genmab <b>Bridging Translational Insights to Clinical Outcomes in B-Cell Malignancies</b> Chair: Martin Hutchings, Copenhagen, DK

## WEDNESDAY, 18 JUNE

Article no.

08:30 – 09:15 **“MEET THE PROFESSOR” SESSIONS**

5 parallel sessions

<b>Room A</b>	<b>Classic Hodgkin lymphoma</b> Andrew M. Evens, New Brunswick, NJ, US	EB5
<b>Room B</b>	<b>Diffuse large B-cell lymphoma and high-grade lymphoma</b> Grzegorz S. Nowakowski, Rochester, MN, US	N/A
<b>Cinema Corso</b>	<b>Multiple myeloma</b> Francesca Gay, Turin, IT	EB6
<b>Auditorium, West Campus USI</b>	<b>Marginal zone lymphomas</b> Sonali M. Smith, Chicago, IL, US	EB11
<b>Polivalente room, East Campus USI</b>	<b>Follicular lymphoma</b> Jessica Okosun, London, UK	EB10

09:30 – 10:15 **“MEET THE PROFESSOR” SESSIONS**

5 parallel sessions

<b>Room A</b>	<b>Nodular lymphocyte-predominant Hodgkin lymphoma</b> <b>Diagnosis</b> - Elias Campo, Barcelona, ES <b>Management</b> - Peter Borchmann, Cologne, DE	EB2
<b>Room B</b>	<b>CLL and Richter</b> Matthew S. Davids, Boston, MA, US	EB3
<b>Cinema Corso</b>	<b>Multiple myeloma (repetition)</b> Francesca Gay, Turin, IT	EB6
<b>Auditorium, West Campus USI</b>	<b>T-cell redirecting therapies</b> Gloria Iacoboni, Barcelona, ES	EB7
<b>Polivalente room, East Campus USI</b>	<b>Waldenström Macroglobulinemia</b> Steven P. Treon, Boston, MA, US	EB12

10:15 – 10:35 **Marquee Parco Ciani** COFFEE BREAK

10:35 – 12:00	<b>EDUCATIONAL SYMPOSIA</b> 2 parallel sessions	
	<b>Room A, broadcast in Cinema Corso</b>	<b>MANTLE CELL LYMPHOMA</b> Chair: Martin Dreyling, Munich, DE
10:35		<b>The biomarkers we need</b> EB13 Simone Ferrero, Turin, IT
11:00		<b>First line therapy: BTKi? Transplant?</b> EB14 Martin Dreyling, Munich, DE
11:25		<b>Relapsed disease: sequencing</b> EB15 Eva Giné Soca, Barcelona, ES
11:50		Panel discussion
	<b>Room B, broadcast in Marquee Parco Ciani, Auditorium, Polivalente room</b>	<b>CLONAL PRECURSORS</b> Chair: Markus Manz, Zurich, CH
10:35		<b>Clonal hematopoietic stem cell precursors</b> EB16 Markus Manz, Zurich, CH
10:55		<b>Clonal T-cell precursors</b> EB17 Claire Dearden, London, UK
11:15		<b>Clonal B-cell precursors</b> EB18 Paolo Ghia, Milan, IT
11:35		<b>Clonal plasma cell precursors</b> EB19 Angela Dispenzieri, Rochester, MN, US
11:55		Panel discussion
12:00 – 13:00	<b>Marquee Parco Ciani</b>	<b>LUNCH TIME AND POSTER VIEWING</b> Posters are on display throughout the Conference during the Marquee Parco Ciani opening hours. The list of poster topics is available on page 65.
13:00 – 14:00	<b>Room A, broadcast in all rooms</b>	<b>OPENING OF THE CONFERENCE</b> WELCOME AND INTRODUCTORY REMARKS Franco Cavalli, Bellinzona, CH

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

	<b>HENRY KAPLAN MEMORIAL LECTURES</b>	
		Laudatio: Franco Cavalli, Bellinzona, CH
		<b>Equal parts dreams, luck and madness: conjuring a new future for lymphoma therapy</b> 001 Bruce D. Cheson, Bethesda, MD, US
		<b>The road to disease discovery: a personal journey</b> 002 Elaine S. Jaffe, Bethesda, MD, US
14:00 – 15:15	<b>Room A, broadcast in all rooms</b>	<b>PLENARY SESSION</b> Co-chairs: Franco Cavalli, Bellinzona, CH and Catherine Thieblemont, Paris, FR
14:00		<b>Large B-cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) identify subgroups with greatest benefit from CD19 CAR T-cell therapy</b> 005 David A. Russler-Germain, St. Louis, US
14:15		Discussant: Stephen M. Ansell, Rochester, MN, US
14:25		<b>Feasibility of ctDNA and PET guided therapy in untreated DLBCL. Preliminary results of the SAKK 38/19 phase II trial</b> 006 Anastasios Stathis, Bellinzona, CH
14:40		Discussant: Mark Roschewski, Bethesda, MD, US
14:50		<b>Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/ refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase III POLARGO trial</b> 007 Juan-Manuel Sancho, Barcelona, ES
15:05		Discussant: Laurie H. Sehn, Vancouver BC, CA
15:15 – 15:45	<b>Marquee Parco Ciani</b>	COFFEE BREAK
15:45 – 16:45	<b>Room A, broadcast in all rooms</b>	<b>AACR – ICML JOINT SESSION</b> <b>The role of artificial intelligence in oncology</b> Co-chairs: Francesco Bertoni, Bellinzona, CH and Margaret Foti, Philadelphia, PA, US

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------



15:45	The role of AI in pathologic diagnosis Pierre Brousset, Toulouse, FR	008
16:05	The role of AI in imaging readings Irene Buvat, Paris, FR	009
16:25	The role of AI in clinical trial design Stefan Michiels, Villejuif, FR	010
17:00 – 18:00 <b>“FOCUS ON...” SESSIONS</b> 5 parallel sessions		
<b>Room A</b>	<b>FOLLICULAR LYMPHOMA</b> Co-chairs: Sonali M. Smith, Chicago, IL, US and Stefano Luminari, Reggio Emilia, IT	
17:00	<b>Follicular lymphoma epidemiology and outcomes in England 2014-2021: preliminary analysis from the UNCOVER Study Group</b> Kim M. Linton, Manchester, UK	096
17:10	<b>Mutation signatures involving epigenetic modifiers predict follicular lymphoma response to radiotherapy</b> N. Ari Wijetunga, Chapel Hill NC, US	097
17:20	<b>Fludarabine, cyclophosphamide and rituximab (FCR) as initial treatment for high tumour burden follicular lymphoma: Final results of the UK phase III PACIFICO trial</b> Andrew Pettitt, Liverpool, UK	098
17:30	<b>Fixed duration subcutaneous mosunetuzumab in patients with previously untreated high-tumor burden follicular lymphoma: interim results from the Phase II MorningSun study</b> L. Elizabeth Budde, Duarte, CA, US	099
17:40	<b>Tazemetostat in Combination with R-CHOP in Patients with high-risk, frontline Follicular Lymphoma (Epi-RCHOP) in need of therapy: a phase II study from the LYSA</b> Loic Ysebaert, Toulouse, FR	100

17:50	<b>Valemetostat monotherapy in patients with relapsed or refractory follicular lymphoma: primary results of the phase 2 VALYM study from the LYSA group</b> Emmanuel Bachy, Lyon, FR	101
<b>Room B, broadcast in Marquee Parco Ciani</b>	<b>NEW CELLULAR THERAPIES</b> Co-chairs: Gloria Iacoboni, Barcelona, ES and Federico Simonetta, Geneva, CH	
17:00	<b>High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL)</b> Maria T. Kuipers, Amsterdam, NL	102
17:10	<b>A Phase 1 Study of KITE-363 Anti-CD19/CD20 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma</b> Marie José Kersten, Amsterdam, NL	103
17:20	<b>A GLOBAL PHASE 1B STUDY OF JNJ-90014496, A CD19/CD20 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)</b> Krish Patel, Nashville, TN, US	104
17:30	<b>Interim Results of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel in Relapsed/Refractory Diffuse Large B Cell Lymphoma</b> Nirav N. Shah, Milwaukee, WI, US	105
17:40	<b>LYL314, a CD19/CD20 CAR T-cell candidate enriched for CD62L+ stem-like cells, achieves high rates of durable complete responses in R/R large B-cell lymphoma</b> Akil Merchant, Los Angeles, CA, US	106

17:50	<b>Results from the dose-finding part of LuminICE-203 Phase 2 study: Acimtamig (AFM13) in combination with AlloNK (AB-101) in patients with relapsed / refractory Hodgkin lymphoma</b> Tatyana Feldman, Hackensack, NJ, US	107
<b>Cinema Corso</b>	<b>ONGOING TRIALS</b> Co-chairs: Kerry J. Savage, Vancouver BC, CA and Grzegorz S. Nowakowski, Rochester, MN, US	
17:00	<b>A Phase 3 Trial of Obinutuzumab and Venetoclax With or Without Acalabrutinib in Patients with High Risk Chronic Lymphocytic Leukemia: CLL16 trial of the GCLLSG</b> Nadine Kutsch, Cologne, DE	OT1
17:10	<b>CLL18/MOIRAI trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in treatment-naïve CLL/SLL</b> Paula Cramer, Cologne, DE	OT2
17:20	<b>BGB-11417-302, A Phase 3, Randomized, Double-Blind Study of Sonrotoclax (BGB-11417) + Zanubrutinib Vs Placebo + Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma</b> Martin Dreyling, Munich, DE	OT3
17:30	<b>GOLSEEK-1: A Phase 3, Double-Blind, Randomized Study of Golcadomide + R-CHOP vs Placebo + R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma</b> Grzegorz S. Nowakowski, Rochester, MN, US	OT4
17:40	<b>GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma</b> Weili Zhao, Shanghai, CN	OT5

17:50	<b>AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy to Immuno-oncology for Children &amp; Adults with Newly Diagnosed Stage I/II Hodgkin Lymphoma</b> Jennifer Seelisch, London ON, CA	OT6
<b>Auditorium, West Campus USI</b>	<b>RADIATION THERAPY</b> Co-chairs: Bouthaina S. Dabaja, Houston, TX, US and Lena Specht, Copenhagen, DK	
17:00	<b>Local control with response-adapted very low dose radiotherapy (RA-VLDRT) of 4 Gy for indolent non-Hodgkin lymphoma</b> Nikhil P. Mankuzhy, New York, NY, US	108
17:10	<b>Ultra-low dose radiotherapy (ULDR) (4Gy) for indolent orbital adnexal lymphomas (IOAL): An International Lymphoma Radiation Oncology Group study</b> Lilly Shen, Melbourne VIC, AU	109
17:20	<b>High PFS with low infield recurrences after low dose radiotherapy and Obinutuzumab in early stage nodal follicular lymphoma: final results of the GAZAI study (GLA 2018-3)</b> Klaus Herfarth, Heidelberg, DE	110
17:30	<b>BOOM-BOOM Radiation Prior to Lisocabtagene Maraleucel Is Feasible and Contributes to High Complete Response Rates For Aggressive B-cell Non-Hodgkin Lymphoma</b> Christopher D'Angelo, Omaha, NE, US	111
17:40	<b>Phase I Study of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas</b> Brandon S. Imber, New York, NY, US	112
17:50	<b>Can Salvage Radiotherapy Achieve Durable Local Control in Relapsed/Refractory Large B-Cell Lymphoma Post-CAR T Failure?</b> Chirayu Patel, Boston, MA, US	113

<b>Polivalente room, East Campus USI</b>	<b>EXPERIMENTAL THERAPEUTICS</b> Co-chairs: Georg Lenz, Münster, DE and Patrizia Mondello, Rochester, MN, US	
17:00	<b>Systematic investigation of disease- and genotype-specific vulnerabilities in primary blood cancer using high-throughput ex vivo drug screening</b> Kevin D. Hofer, Zurich, CH	114
17:10	<b>The BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax shows anti-tumor activity as single agents and in combination in marginal zone lymphoma models</b> Alberto J. Arribas, Bellinzona, CH	115
17:20	<b>The Toll-Like Receptor 7/8 Pathway Has Prognostic Significance and is a Therapeutic Target in CNS Lymphomas</b> James L. Rubenstein, San Francisco, CA, US	116
17:30	<b>DUAL TARGETING CD30/PDL-1 CAR-T CELLS OUTPERFORMS CD30 CAR-T CELLS IN A NEWLY DEVELOPED IMMUNOSUPPRESSIVE 2D CELLULAR MODEL MIMICKING CLASSIC HL MICROENVIRONMENT</b> Vincenzo M. Perriello, Perugia, IT	117
17:40	<b>CDK7 enables the functional crosstalk between lymphoma and microenvironment (TME) cells in peripheral T-cell lymphoma (PTCL)</b> Khouloud Kouidri, New York, NY, US	118
17:50	<b>LIS22: An Effective Multimodal Polyclonal Antibody Targeting T-Cell Malignancies</b> Firas Bassissi, Nantes, FR	119

19:00 – 20:30	<b>2 parallel satellite symposia</b>	
<b>Room A</b>	AbbVie <b>Navigating the Rapidly Changing Treatment Landscape in Follicular Lymphoma (FL)</b> Chair: Kim M. Linton, Manchester, UK	
<b>Room B</b>	Takeda <b>Curative approaches in advanced Hodgkin lymphoma: individualized choices based on the latest data</b> Chair: Anna Sureda Balari, Barcelona, ES	IP01

## THURSDAY, 19 JUNE

Article no.

### 08:15 – 09:00 “MEET THE PROFESSOR” SESSIONS

5 parallel sessions

<b>Room A</b>	<b>Non-clonal lymphoproliferative diseases</b> <b>Diagnosis</b> - Stefan Dirnhofer, Basel, CH <b>Management of Castleman disease</b> - Angela Dispenzieri, Rochester, MN, US	EB4
<b>Room B</b>	<b>Diffuse large B-cell lymphoma and high-grade lymphoma</b> (repetition) Grzegorz S. Nowakowski, Rochester, MN, US	N/A
<b>Cinema Corso</b>	<b>Peripheral T-cell lymphoma</b> Won Seog Kim, Seoul, KR	EB8
<b>Auditorium, West Campus USI</b>	<b>Waldenström Macroglobulinemia</b> (repetition) Steven P. Treon, Boston, MA, US	EB12
<b>Polivalente room, East Campus USI</b>	<b>Marginal zone lymphomas</b> (repetition) Sonali M. Smith, Chicago, IL, US	EB11

### 09:15 – 10:30 “CHALLENGING CASES DISCUSSION” SESSIONS

3 parallel sessions

<b>Room A</b>	<b>AGGRESSIVE B-CELL LYMPHOMAS</b> Chair: Ranjana H. Advani, Palo Alto, CA, US Presenter: Maria Cristina Piroso, Bellinzona, CH Discussants: Brad S. Kahl, Saint Louis, MO, US, Laurie Sehn, Vancouver BC, CA, Lena Specht, Copenhagen, DK	
<b>Cinema Corso</b>	<b>T-CELL LYMPHOMA</b> Chair: Won Seog Kim, Seoul, KR Presenter: Ilaria Romano, Bellinzona, CH Discussants: Won Seog Kim, Seoul, KR, Kerry J. Savage, Vancouver BC, CA, Pier Luigi Zinzani, Bologna, IT	
<b>Auditorium, West Campus USI</b>	<b>PAEDIATRIC LYMPHOMAS</b> Panelists: Amos Burke, Birmingham, UK, Francesco Ceppi, Lausanne, CH, Wilhelm Wössmann, Hamburg, DE, Jamie E. Flerlage, Rochester, NY, US	

09:15 – 10:30	<b>Room B, Broadcast in Marquee Parco Ciani</b>	<b>SESSION 1: IMAGING AND RADIOMICS</b> Co-chairs: Anne-Ségolène Cottreau, Paris, FR and Martin Hutchings, Copenhagen, DK	
09:15		<b>Predicting 2-Year Time to Progression in Diffuse Large B-Cell Lymphoma Using Artificial Intelligence on Whole-Body PET Scans</b> Maria C. Ferrandez Ferrandez, Amsterdam NL	011
09:30		<b>Imaging Biomarkers for the Definition of Response in the GHSG HD18, GHSG HD21 and LYSA AHL2011 Trials for Advanced-stage Hodgkin Lymphoma</b> Justin Ferdinandus, Cologne, DE	012
09:45		<b>Prognostic Value of the Combination of Radiomics Parameters Measured on Baseline FDG PET/CT in Primary Mediastinal B-Cell Lymphoma</b> Pierre Decazes, Rouen, FR	013
10:00		<b>Performance of baseline and end-of-treatment FDG-PET radiomics in patients with Peripheral T-Cell Lymphoma: Data from International Prospective T-Cell Project 2.0</b> Tetiana Skrypets, Bari, IT	014
10:15		<b>Early PET response predicts risk of relapse after 2L axi-cel in large B-cell lymphoma</b> Andrea Kuhn, London, UK	015
09:15 – 10:30	<b>Polivalente room, Campus Est USI</b>	<b>SESSION 2: BASIC AND TRANSLATIONAL RESEARCH LYMPHOMA EPIGENETICS</b> Co-chairs: Ari M. Melnick, New York, NY, US and Sandrine Roulland, Marseille, FR	
09:15		<b>Epigenetic mechanisms and therapy for B-cell lymphomas</b> Ari M. Melnick, New York, NY, US	016
09:35		<b>Super-enhancer hypermutation in DLBCL: targeting the glucocorticoid receptor pathway</b> Riccardo Dalla-Favera, New York, NY, US	017



09:55		<b>Epigenetic vulnerabilities: pre-clinical and clinical evidences</b> Franck Morschhauser, Lille, FR	018
10:15		<b>Multi-omic Profiling of Dark Zone Lymphomas Uncovers Dysregulated Gene Regulatory Networks Reflecting DZ-LZ B-cell Transition Dynamics</b> Amos Fong, Vancouver BC, CA	019
10:30 – 11:00	<b>Marquee Parco Ciani</b>	COFFEE BREAK	
11:00 – 12:00	<b>Room A, broadcast in Room B, Marquee Parco Ciani, Cinema Corso, Auditorium</b>	<b>SESSION 3: HODGKIN LYMPHOMA FROM CHILDREN TO ADULTS</b> Co-chairs: Ranjana H. Advani, Palo Alto, CA, US and Wilhelm Wössmann, Hamburg, DE	
11:00		<b>Impact of EBV Status and Histology on Outcomes with Nivolumab-AVD versus Bv-AVD in Patients Enrolled on SWOG S1826</b> Sairah Ahmed, Houston, TX, US	020
11:15		<b>Prognostic Value of Circulating Tumor DNA in Patients with Advanced Stage Classic Hodgkin Lymphoma Treated on SWOG S1826</b> Alex F. Herrera, Duarte, CA, US	021
11:30		<b>Prognostic value of baseline total metabolic tumor volume (TMTV) and tumor spread (Dmax) in advanced Hodgkin lymphoma: Ancillary study of the AHL2011 trial</b> Cédric Rossi, Dijon, FR	022
11:45		<b>Radiotherapy improves progression-free survival for stage IA NPLHL: A retrospective report from the Global nLPHL One Working Group (GLOW)</b> Jamie E. Flerlage, Rochester, NY, US	023

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

11:00 – 12:00	<b>Polivalente room, East Campus USI</b>	<b>“FOCUS ON...” SESSION CROSS-CUTTING TOPICS</b> Co-chairs: Carlos S. Chiattonne, Sao Paulo, BR and Annarita Conconi, Biella, IT	
11:00		<b>Detection of Intratumoral microorganisms and their impact on outcomes in untreated diffuse large B-cell lymphoma</b> Paola Ghione, New York, NY, US	120
11:10		<b>Influence of health disparities (HD) on clinical outcomes in patients (pts) with diffuse large B cell lymphoma (DLBCL) in the United States</b> Alvaro J. Alencar, Miami, FL, US	121
11:20		<b>Identifying Harmful Hyperinflammation in Diffuse Large B-cell Lymphoma using the OHI (Optimized HLH Inflammatory) Index - Discovery and Validation in Real-World Patients</b> Thomas E. Witzig, Rochester, MN, US	122
11:30		<b>Updated Interim Results of Sonrotoclast + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): an All-Oral Treatment</b> Binod Dhakal, Milwaukee, WI, US	123
11:40		<b>Updated Results: Ph 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with EBV+ PTLD after Rituximab+/- Chemotherapy Failure</b> Sylvain Choquet, Paris, FR	124
11:50		<b>Rituximab in combination with bendamustine achieves rapid and sustained responses in anti-MAG neuropathy</b> Damien Roosweil, Paris, FR	125
12:00 – 13:00	<b>Marquee Parco Ciani</b>	<b>LUNCH TIME and POSTER VIEWING</b>	
12:30 – 13:00	<b>Marquee Parco Ciani</b>	<b>POSTER PRESENTATIONS</b> Presenters of odd-numbered posters will be by their posters for a Q&A session with attendees.	

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

13:00 – 13:45	<b>Room A, broadcast in all rooms</b>	<b>GIANNI BONADONNA MEMORIAL LECTURE</b> Supported by the European School of Oncology Foundation – ESOF Chair: Franco Cavalli, Bellinzona, CH  Laudatio: Riccardo Dalla-Favera, New York, NY, US  <b>Molecular classification of aggressive B-cell lymphomas</b> David W. Scott, Vancouver BC, CA	003
---------------	---------------------------------------	--	-----

14:00 – 15:30 **PARALLEL SESSIONS**  
3 parallel sessions

	<b>Room A, broadcast in Room B, Marquee Parco Ciani, Cinema Corso</b>	<b>SESSION 4: FOLLICULAR LYMPHOMA</b> Co-chairs: Jonathan W. Friedberg, Rochester, NY, US and Judith Trotman, Sydney NSW, AU	
14:00		<b>Unveiling Follicular Lymphoma Heterogeneity: A Single-Cell Atlas Reveals Prognostic Cellular Ecosystems and Novel Biomarkers Associated with High-Risk</b> Sandrine Roulland, Marseille, FR	024
14:15		<b>Response-adapted very low dose radiotherapy (RA-VLDRT) for potentially curable indolent non-Hodgkin lymphoma</b> Nikhil P. Mankuzhy, New York, NY, US	025
14:30		<b>Ibrutinib-Rituximab Versus Placebo-Rituximab in Patients With Previously Untreated Follicular Lymphoma (FL): Primary Analysis of the Phase 3 PERSPECTIVE Study</b> David Belada, Hradec Králové, CZ	026
14:45		<b>Mosunetuzumab (mosun) Produces Durable Benefit in Patients (pts) with Newly Diagnosed Follicular Lymphoma (FL): Extended Follow up of the MITHIC-FL1 Trial</b> Lorenzo Falchi, New York, NY, US	027

15:00		<b>Outcomes From the Phase 3 inMIND Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and Rituximab (R) for Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)</b> Laurie H. Sehn, Vancouver BC, CA	028
15:15		<b>A Comparative Analysis of Histologic Transformation of Follicular Lymphoma at Diagnosis (composite lymphoma) and Sequentially Transformed Follicular Lymphoma</b> Carla Casulo, Rochester, NY, US	029

14:00 – 16:35	<b>Auditorium, West Campus USI</b>	<b>SESSION 5: PEDIATRIC LYMPHOMAS</b> Co-chairs: Francesco Ceppi, Lausanne, CH and Wilhelm Wössmann, Hamburg, DE	
14:00		<b>Exosomes and miRs in childhood NHL and Hodgkin's lymphoma</b> Lara Mussolin, Padua, IT	030
14:25		<b>Relapsed/refractory mature B-NHL in children and adolescents</b> Amos Burke, Birmingham, UK	031
14:50		<b>Metabolic-only response assessment allows radiation omission for majority with classical Hodgkin lymphoma and maintains excellent outcomes: a PHC phase 2 study cHOD17</b> Jamie E. Flerlage, Rochester, NY, US	032
15:00		<b>Glofitamab plus R-ICE or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: updated analysis from the iMATRIX-GLO study</b> Veronique Minard-Colin, Villejuif, FR	033
15:10		<b>Targeted Immunotherapy in Children, Adolescents, and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma, a single center experience</b> Mitchell S. Cairo, New York, NY, US	034
15:20		BREAK	

15:45	<b>Second Malignant Neoplasm Risk after Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma on Children's Oncology Group AHOD1331</b> Sarah Allison Milgrom, Aurora, CO, US	035
15:55	<b>Frequency of fusion genes and their clinical impacts in Chinese pediatric patients with T-cell lymphoblastic lymphoma</b> Yonghong Zhang, Beijing, CN	036
16:05	<b>Patterns of fatigue in high-risk pediatric Hodgkin lymphoma (HL) treated with Pediatric Hodgkin Consortium (PHC) brentuximab vedotin-containing European-derived regimens</b> Angela M. Feraco, Boston, MA, US	037
16:15	<b>Clinical analysis of 53 cases of relapsed or refractory childhood ALK + anaplastic large cell lymphoma</b> Kai Wang, Beijing, CN	038
16:25	<b>Impact of Time of Onset on Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes: Results from a Prospective/ Retrospective Multicenter Study</b> Lianna Jean Marks, Palo Alto, CA, US	039
14:00 - 15:30	<b>Polivalente room, East Campus USI</b> <b>SESSION 6: LIQUID BIOPSY FOR RESPONSE ASSESSMENT</b> Co-chairs: Mark Roschewski, Bethesda, MD, US and Christiane Pott, Kiel, DE	
14:00	<b>The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma</b> Daniel J. Hodson, Cambridge, UK	040
14:15	<b>Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial</b> Martine E.D. Chamuleau, Amsterdam, NL	041

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

14:30	<b>Circulating Tumor DNA for Monitoring Primary Mediastinal B-cell Lymphoma in Complement to PET: A Prospective Multicenter LYSA Study</b> Vincent Camus, Rouen, FR	042
14:45	<b>Circulating tumor DNA sequencing reveals rapid response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma: Molecular insights from the GHSG NIVAHL trial</b> Jan-Michel Heger, Cologne, DE	043
15:00	<b>Value of end of induction MRD in ctDNA versus peripheral blood/bone marrow for early relapse prediction in advanced follicular lymphoma: a RELEVANCE ancillary study</b> Alexis Claudel, Creteil, FR	044
15:15	<b>Multi-targeted therapy with ViPOR in mantle cell lymphoma (MCL): Updated analysis of efficacy and minimal residual disease (MRD)</b> Christopher Melani, Bethesda, MD, US	045
15:30 – 15:45	<b>Marquee Parco Ciani</b> COFFEE BREAK	
15:45 – 17:00	<b>PARALLEL SESSIONS</b> 3 parallel sessions	
	<b>Room A, broadcast in Cinema Corso</b> <b>SESSION 7: MANTLE CELL LYMPHOMA</b> Co-chairs: Steven Le Gouill, Paris, FR and Yuqin Song, Beijing, CN	
15:45	<b>Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial</b> Martin Dreyling, Munchen, DE	046
16:00	<b>Ibrutinib and Rituximab is superior to immunochemotherapy in previously untreated mantle cell lymphoma despite lower rates of MRD negativity</b> David Lewis, Plymouth, UK	047

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

16:15	<b>Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of POLARIS Multicenter Phase II Study</b> Zheng Song, Tianjin, CN	048
16:30	<b>Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) + Zanubrutinib Induces High Rate of Complete Remission in Relapsed/Refractory Mantle Cell Lymphoma</b> Stephen S. Opat, Clayton VIC, AU	049
16:45	<b>Fixed-duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a Phase II study of relapsed/refractory post-BTKi mantle cell lymphoma</b> L. Elizabeth Budde, Duarte, CA, US	050
<b>Room B, broadcast in Marquee Parco Ciani</b>	<b>SESSION 8: MARGINAL ZONE AND LYMPHOPLASMATIC LYMPHOMAS</b> Co-chairs: Antonio Salar, Barcelona, ES and Ariela Noy, New York, NY, US	
15:45	<b>Long-term benefit and molecular features of patients with HCV-associated indolent lymphomas treated with direct-acting antivirals: 6-year follow-up of the FIL_BaT study</b> Michele Merli, Milan, IT	051
16:00	<b>Rituximab and ibrutinib combination is safe and effective in untreated Extranodal Marginal Zone Lymphomas: First analysis of the IELSG47/MALIBU phase II study</b> Annarita Conconi, Biella, IT	052
16:15	<b>A Phase II Study of Acalabrutinib, Lenalidomide and Rituximab in Patients with Previously Untreated Indolent B-cell Lymphoma</b> Paolo Strati, Houston, TX, US	053

16:30	<b>Fixed duration treatment of bendamustine-rituximab and acalabrutinib in frontline Waldenström's Macroglobulinemia: deep molecular responses in high-risk patient subsets</b> Neil L. Berinstein, Toronto ON, CA	054
16:45	<b>Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL study</b> M. Lia Palomba, New York, NY, US	055
15:45 – 17:00	<b>Polivalente room, East Campus USI</b> <b>SESSION 9: GENOMICS AND CLONAL HEMATOPOIESIS</b> Co-chairs: Elias Campo, Barcelona, ES and Leticia Quintanilla-Martinez, Tübingen, DE	
15:45	<b>Genomic Analysis of Mature B-cell Lymphomas</b> Ryan D. Morin, Vancouver BC, CA	056
16:00	<b>CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL</b> Riccardo Moia, Novara, IT	057
16:15	<b>Detection and clinical impact of subclonal TP53 mutations and CHIP in patients with MCL: Results from the EU-MCL network trials</b> Mouhamad Khouja, Kiel, DE	058
16:30	<b>Clonal hematopoiesis is associated with persisting anemia in elderly patients treated for DLBCL: Analysis of the phase 3 POLAR BEAR trial</b> Simon Husby, Copenhagen, DK	059
16:45	<b>Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma</b> Deborah Piffaretti, Bellinzona, CH	060
17:15 – 18:15	<b>“FOCUS ON...” SESSIONS</b> 5 parallel sessions	

**Room A**  
**HODGKIN LYMPHOMA**  
Co-chairs: Alex F. Herrera, Duarte, CA, US and Maria Cristina Piroso, Bellinzona, CH



17:15	<b>The Early-stage classic Hodgkin Lymphoma International Prognostication Index (E-HIPI): an individualized prediction model utilizing objective and continuous variables</b> Andrew M. Evens, New Brunswick, NJ, US	126
17:25	<b>Health-Related Quality of Life (HRQoL) endpoints of the Phase III Intergroup S1826 Advanced-Stage, Classic Hodgkin Lymphoma (cHL) trial</b> Kelly Davison, Montreal, Quebec ON, CA	127
17:35	<b>Adolescent/ young adult (AYA) patients with high-risk stage 2 classic Hodgkin lymphoma have similar outcomes to stage 3 or 4 with 6 cycles of ABVD chemotherapy</b> Jowon Laura Kim, Vancouver BC, CA	128
17:45	<b>Pembrolizumab and radiation therapy alone as an alternative to transplant for localized failure after chemotherapy in Hodgkin Lymphoma: A multicenter phase II study</b> Alexandra D. Dreyfuss, New York, NY, US	129
17:55	<b>Tislelizumab, an Anti-PD-1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Final Analysis from the LYSA Phase 2 TIRHOL Study BGB-A317-210</b> Hervé Ghesquière, Pierre Bénite, FR	130
18:05	<b>Improved Outcomes over Time for Relapsed Hodgkin Lymphoma after Autologous and Allogeneic Stem Cell Transplant: From EBMT Lymphoma Working Party</b> Ali Bazarbachi, Beirut, LB	131
<b>Room B</b>	<b>MANTLE CELL LYMPHOMA</b> Co-chairs: Clementine Sarkozy, Saint Cloud, FR and Brad S. Kahl, St. Louis, MO, US	
17:15	<b>Clinical Impact of Clonal and Subclonal Driver Alterations in Mantle Cell Lymphoma Subtypes</b> Cristina López, Barcelona, ES	132

17:25	<b>Long-term Survival Trends in Advanced-Stage Mantle Cell Lymphoma: A Pooled Analysis of Six Randomized Phase III Trials from 1996 to 2020</b> Eva Hoster, Munich, DE	133
17:35	<b>Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study</b> Michael Wang, Houston, TX, US	134
17:45	<b>Long-Term Follow up of the VALOR (venetoclax, lenalidomide, rituximab) in patients w/ untreated mantle cell lymphoma</b> Tycel Jovelle Phillips, Duarte, CA, US	135
17:55	<b>Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the ECHO trial</b> Pier Luigi Zinzani, Bologna, IT	136
18:05	<b>Ibrutinib added to MCL treatment has strong impact on MRD response and disease kinetics: results from the TRIANGLE trial</b> Mouhamad Khouja, Kiel, DE	137
<b>Cinema Corso</b>	<b>CART-CELLS OUTCOMES</b> Co-chairs: Stephen J. Schuster, Philadelphia, PA, US and Catherine Thieblemont, Paris, FR	
17:15	<b>Phase 2 ELARA Trial 4-year Update: Clinical Outcomes of Tisagenlecleucel in Patients (pts) With High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL)</b> Catherine Thieblemont, Paris, FR	138
17:25	<b>Enhanced CAR T-cell Expansion and Durable Complete Responses with NKTR-255 Plus Lisocabtagene Maraleucel in Relapsed/Refractory Large B-cell Lymphoma</b> Cameron J. Turtle, Seattle, WA, US	139

17:35	<b>Phase 2 trial of lisocabtagene maraleucel (liso-cel) in combination with acalabrutinib in relapsed/refractory large B-cell lymphomas (LBCL)</b> Patrick C. Johnson, Boston, MA, US	140
17:45	<b>CD30 CAR-T in Relapsed and Refractory CD30+ Lymphomas: Long-Term Follow-Up of a Phase Ib/II Clinical Trial</b> Daniel Reef, Chapel Hill, NC, US	141
17:55	Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): impact of prior lines of therapy, bendamustine exposure, and disease progression ≤24 months of initial systemic therapy Sairah Ahmed, Houston, TX, US	142
18:05	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Richter Transformation to Large B-Cell Lymphoma (RT-LBCL) Allison M. Winter, Cleveland, OH, US	143
<b>Auditorium, West Campus USI</b>	<b>EARLY CLINICAL TRIALS</b> Co-chairs: Paola Ghione, New York, NY, US and Franck Morschhauser, Lille, FR	
17:15	<b>Updated Efficacy/Safety of the Bruton Tyrosine Kinase (BTK) Degradar BGB-16673 in Relapsed/Refractory (R/R) CLL/SLL: Results From the Ongoing Phase 1 CaDAnCe-101 Study</b> John F. Seymour, Melbourne VIC, AU	144
17:25	<b>Phase 1/2 Studies of DZD8586 in CLL/SLL Patients after Covalent or Non-covalent BTK Inhibitors and BTK Degraders</b> Jianyong Li, Nanjing, CN	146
Anna Maria Frustaci, Milan, IT	<b>Updated Efficacy &amp; Safety of BTK Degradar BGB-16673 in Patients (Pts) with Relapsed/Refractory Waldenström Macroglobulinemia (R/R WM): Ongoing Phase 1 CaDAnCe-101 Results</b> Anna Maria Frustaci, Milan, IT	147

17:45	<b>Sonrotoclax (BGB-11417), A Novel BCL2 Inhibitor, Plus Zanubrutinib (Zanu) Demonstrates Deep and Durable Responses in Relapsed/Refractory CLL/SLL: Updated Phase 1 Results</b> Chan Y. Cheah, Perth WA, AU	145
17:55	<b>Golcadomide ± Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Phase 1/2 Results</b> Emmanuel Bachy, Lyon, FR	148
18:05	<b>First-in-Human Phase 1 Study of DR-01, a Non-Fucosylated Anti-CD94 Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization</b> Swaminathan P. Iyer, Houston, TX, US	149
<b>Polivalente room, East Campus USI</b>	<b>LIQUID BIOPSY</b> Co-chairs: Vincent Camus, Rouen, FR and Adalgisa Condoluci, Bellinzona, CH	
17:15	<b>Circulating tumour DNA analysis in follicular lymphoma treated with first-line venetoclax, lenalidomide and obinutuzumab on the LEVERAGE trial</b> Chan Y. Cheah, Perth WA, AU	150
17:25	<b>Clinical validity of noninvasive genotyping of MCL at diagnosis from blood plasma by circulating tumor DNA profiling</b> Benoit Tessoulin, Nantes, FR	151
17:35	<b>Glofitamab+R-CHOP in patients with previously untreated large B-cell lymphoma defined as high risk by circulating tumor DNA (ctDNA) dynamics: primary results</b> Marcel Nijland, Groningen, NL	152
17:45	<b>Harnessing systemic inflammation with circulating tumor DNA improves survival prediction in large B-cell lymphoma</b> Sirpa Leppä, Helsinki, FI	153

17:55	<b>CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA</b> Riccardo Dondolin, Novara, IT	154
18:05	<b>Circulating tumor DNA (ctDNA) for response prediction and genetic characterization of Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) receiving Glofitamab treatment</b> Carmelo Carlo-Stella, Milan, IT	155
19:00 – 20:30 <b>4 parallel satellite symposia</b>		
<b>Room A</b>	Allogene Therapeutics <b>Emerging Paradigms in DLBCL Response Assessment and Treatment: Novel MRD and CAR T Strategies to Improve Outcomes</b> Co-chairs: Jason Westin, Houston, TX, US and Alex F. Herrera, Duarte, CA, US	
<b>Room B</b>	AbbVie <b>Treating Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)</b> Chair: Martin Dreyling, Munich, DE	
<b>Auditorium, West Campus USI</b>	Pierre Fabre <b>Charting a new course in EBV+ PTLD with allogeneic T-cell immunotherapy</b> Chair: Eva González Barca, Barcelona, ES	
<b>Room E</b>	Follicular Lymphoma Foundation <b>Follicular Lymphoma: Charting our Progress Towards a Cure</b> Chair: Mitchell Smith, Washington, DC, US	

## FRIDAY, 20 JUNE

Article no.

### 08:15 – 09:00 “MEET THE PROFESSOR” SESSIONS

5 parallel sessions

<b>Room A</b>	T-cell redirecting therapies (repetition) Gloria Iacoboni, Barcelona, ES	EB7
<b>Room B</b>	Peripheral T-cell lymphoma (repetition) Won Seog Kim, Seoul, KR	EB8
<b>Cinema Corso</b>	Autoimmune complications of lymphoproliferative diseases Wilma Barcellini, Milan, IT	EB1
<b>Auditorium, West Campus USI</b>	Classic Hodgkin lymphoma (repetition) Andrew M. Evens, New Brunswick, NJ, US	EB5
<b>Polivalente room, East Campus USI</b>	Follicular lymphoma (repetition) Jessica Okosun, London, UK	EB10

### 09:15 – 10:30 PARALLEL SESSIONS

5 parallel sessions

<b>Room A</b>	<b>“CHALLENGING CASES DISCUSSION” SESSION INDOLENT NHL AND CLL</b> Chair: Jonathan W. Friedberg, Rochester, NY, US Presenter: Adalgisa Condoluci, Bellinzona, CH Discussants: Jonathan Friedberg, Rochester, NY, US, David C. Hodgson, Toronto ON, CA, Barbara F. Eichhorst, Cologne, DE	
<b>Room B, broadcast in Marquee Parco Ciani</b>	<b>SESSION 10: NK/T-CELL LYMPHOMA</b> Co-chairs: Won Seog Kim, Seoul, KR and Weili Zhao, Shanghai, CN	
09:15	<b>A Pivotal Study of SHR2554, An Oral Inhibitor Against Enhancer of Zeste Homolog 2 (EZH2), in Relapsed or Refractory (r/r) Peripheral T-cell Lymphoma (PTCL)</b> Yubin Song, Beijing, CN	061

09:30	<b>A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)</b> Shu Cheng, Shanghai, CN	062
09:45	<b>Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study</b> Chuanxu Liu, Shanghai, CN	063
10:00	<b>Nivolumab + GemOx as second-line therapy for peripheral T cell lymphoma in transplant-ineligible patients: final analysis of a sub-cohort of the randomized NIVEAU trial</b> Gerhard Held, Leipzig, DE	064
10:15	<b>Utility of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Extranodal NK/T-cell Lymphoma</b> Ayumi Fujimoto, Tokyo, JP	065
<b>Cinema Corso</b>	<b>“CHALLENGING CASES DISCUSSION” SESSION DIFFICULT PATHOLOGICAL CASES</b> Chair: Elias Campo, Barcelona, ES Presenter: Federico Jauk, Bellinzona, CH Discussants: Stephan Dirnhofer, Basel, CH, Leticia Quintanilla-Martinez, Tübingen, DE	
<b>Polivalente room, East Campus USI</b>	<b>SESSION 11: BASIC AND TRANSLATIONAL RESEARCH (AACR-ICML session) MECHANISMS OF RESISTANCE IN LYMPHOMAS</b> Co-chairs: Margaret A. Shipp, Boston, MA, US and David W. Scott, Vancouver BC, CA	
09:15	<b>Mechanisms of resistance to checkpoint inhibitors</b> Margaret A. Shipp, Boston, MA, US	066
09:35	<b>Mechanisms of resistance to small molecule inhibitors</b> John F. Seymour, Melbourne VIC, AU	067

09:55	<b>Mechanisms of resistance to T-cell redirecting therapies</b> Ash A. Alizadeh, Stanford, CA, US	068
10:15	<b>Escape From CAR-Negative Endogenous CD8 T Cells Drives Resistance to CD19-Directed CAR-T Therapies in Large B-Cell Lymphomas</b> Jonathan H. Schatz, Miami, FL, US	069
09:15 – 12:00	<b>Auditorium, West Campus USI</b> <b>LYMPHOMA RADIOTHERAPY WORKSHOP</b> <b>Low doses, few fractions, and new indications for radiation therapy in haematological malignancies</b> Co-chairs: Umberto Ricardi, Turin, IT and Lena Specht, Copenhagen, DK <i>Organised in collaboration with the International Lymphoma Radiation Oncology Group – ILROG</i>	
09:15	<b>The growing use of radiation therapy of multiple myeloma: Looking for clues for better integration with new therapies</b> Alexandra D. Dreyfuss, New York, NY, US	
09:30	<b>Single fraction of 4 Gy for indolent lymphomas – evidence and clinical guidelines</b> Brandon Imber, New York, NY, US	
09:45	<b>Is adjuvant systemic therapy indicated for patients with early-stage indolent lymphomas treated with radiation therapy – immediate vs. deferred treatment</b> Michael MacManus, Melbourne VIC, AU	
10:00	<b>Response-adapted ultra-low-dose radiation therapy for gastric MALT lymphoma</b> Bouthaina S. Dabaja, Houston, TX, US	
10:15	BREAK	
10:40	<b>Gastric motion and adaptive radiation therapy for gastric lymphoma</b> Peter Meidahl Petersen, Copenhagen, DK	
10:55	<b>Options for consolidation of methotrexate-based response in primary CNS lymphoma – efficacy and safety</b> Kathryn Tringale, La Jolla, CA, US	



11:10	<b>New indications for radiation therapy of mantle cell lymphoma</b> Klaus Herfarth, Heidelberg, DE	
11:25	<b>Few and large fractions (hypofractionation) in modern radiation therapy for haematological malignancies – convenient and safe in selected patients</b> Joanna Yang, St. Louis, MO, US	
11:40	Panel discussion All speakers	
10:30 – 11:00	<b>Marquee Parco Ciani</b>	COFFEE BREAK
11:00 – 12:00	<b>PARALLEL SESSIONS</b> 2 parallel sessions	
	<b>Room A, broadcast in Cinema Corso and Polivalente room</b>	<b>SESSION 12: CHRONIC LYMPHOCYTIC LEUKEMIA</b> Co-chairs: Matthew S. Davids, Boston, MA, US and Barbara F. Eichhorst, Cologne, DE
11:00	<b>The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naïve CLL</b> Barbara F. Eichhorst, Cologne, DE	070
11:15	<b>Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study</b> Paul M. Barr, Rochester, NY, US	071
11:30	<b>SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)</b> Mazyar Shadman, Seattle, WA, US	072

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

11:45	<b>Primary Endpoint Evaluation of a Multicenter Phase 2 Study of Venetoclax in Combination with R-CHOP (VR-CHOP) for Patients with Richter Syndrome</b> Matthew S. Davids, Boston, MA, US	073
	<b>Room B, broadcast in Marquee Parco Ciani</b>	<b>“FOCUS ON...” SESSION</b> <b>DLBCL IN THE ELDERLY</b> Co-chairs: Bruce D. Cheson, Bethesda, MD, US and Maria Gomes da Silva, Lisboa, PT
11:00	<b>Excellent outcome with interim PET adapted treatment reduction in elderly DLBCL pts with favourable prognosis: Results of 288 pts treated in OPTIMAL&gt;60 of the DSHNHL/GLA</b> Lorenz Thurner, Homburg, DE	156
11:10	<b>PET guided omission of radiotherapy in elderly DLBCL pts with less favourable prognosis is safe: Results of 863 patients treated in the OPTIMAL&gt;60 trial of the DSHNHL/GLA</b> Lorenz Thurner, Homburg, DE	157
11:20	<b>EPCORE DLBCL-3: FIXED-DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥75 Y), ANTHRACYCLINE-INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B-CELL LYMPHOMA (LBCL)</b> David Belada, Hradec Králové, CZ	158
11:30	<b>R-Pola-Glo – Chemo-light Frontline Therapy Induces High Response Rates with a favorable Safety Profile in Elderly/Frail Patients with Aggressive Lymphoma</b> Rebecca Wurm-Kuczera, Berlin, DE	159
11:40	<b>VERLen: Tafasitamab, Lenalinomide, plus Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients over 80 y/o or older, a LYSA phase 2 trial</b> Benoit Tessoulon, Nantes, FR	160

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

11:50		<b>Outcomes of Glofitamab and Epcoritamab in R/R DLBCL elderly patients: A Real-World Evidence Study from the CUBIC Consortium</b> Swetha Kambhampati Thiruvengadam, Duarte, CA, US	161
12:00 – 13:00	<b>Marquee Parco Ciani</b>	LUNCH TIME and POSTER VIEWING	
12:30 – 13:00	<b>Marquee Parco Ciani</b>	<b>POSTER PRESENTATIONS</b> Presenters of even-numbered posters will be by their posters for a Q&A session with attendees.	
13:00 – 13:45	<b>Room A, broadcast in all rooms</b>	<b>JOHN ULTMANN MEMORIAL LECTURE</b> Supported by the American Association for Cancer Research – AACR Chair: Franco Cavalli, Bellinzona, CH  Laudatio: T. Andrew Lister, London, UK  <b>Extranodal lymphomas: improved outcome through international collaborative research</b> Emanuele Zucca, Bellinzona, CH	004
14:00 – 15:30	<b>PARALLEL SESSIONS</b> 2 parallel sessions		
	<b>Room A, broadcast in Cinema Corso</b>	<b>SESSION 13: AGGRESSIVE B-CELL LYMPHOMAS</b> Co-chairs: Weili Zhao, Shanghai, CN and Andy Davies, Southampton, UK	
14:00		<b>A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma</b> Jennifer L. Crombie, Boston, MA, US	074
14:15		<b>Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC and BCL2 Rearrangements with DLBCL Morphology</b> Waleed Alduaij, Vancouver BC, CA	075
14:30		<b>Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO</b> Jeremy S. Abramson, Boston, MA, US	076

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

14:45		<b>Outcomes of CAR T-Cell Therapy Versus Autologous HSCT in Patients with Large B-Cell Lymphoma in Complete Remission: an Analysis from the EBMT Lymphoma Working Party</b> Remy Dulery, Paris, FR	077
15:00		<b>Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)</b> Juan Pablo Alderuccio, Miami, FL, US	078
15:15		<b>Outcome of Autologous and Allogenic HCT in Burkitt Lymphoma: An EBMT registry analysis</b> Lorenz Thurner, Homburg, DE	079
	<b>Room B, broadcast in Marquee Parco Ciani</b>	<b>SESSION 14: BIOLOGY OF FOLLICULAR LYMPHOMA</b> Co-chairs: Ryan D. Morin, Vancouver BC, CA and Jessica Okosun, London, UK	
14:00		<b>Whole genome sequencing of serial FL biopsies from 96 patients with follicular lymphoma reveal treatment-specific patterns of tumour evolution</b> Laura K. Hilton, Vancouver BC, CA	080
14:15		<b>Repression of miR-29 via MYC Leads to Increased CD40 Signaling in Transformed Follicular Lymphoma (FL) and Unfavourable Prognosis in FL</b> Daniel Filip, Brno, CZ	081
14:30		<b>Characterizing and Targeting Follicular Lymphoma's Common Progenitor Cells</b> Oscar Atkins, London, UK	082
14:45		<b>Single cell analysis reveals extensive immune exhaustion and memory-cell like origin in Follicular Lymphoma (FL) with increased IRF4 expression</b> Patrizia Mondello, Rochester, MN, US	083

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

15:00	<b>Disrupting follicular dendritic cell interactions and epigenetic regulation to prevent follicular lymphoma progression</b> Wendy Béguelin, New York, NY, US	084
15:15	<b>Patient-Derived lymphoma Spheroids as preclinical models for predicting patient responses to advanced therapies in B-NHL: example of glofitamab in follicular lymphoma</b> Camille Laurent, Toulouse, FR	085
14:00 – 17:00	<b>Auditorium, West Campus USI</b> <b>SESSION 15: ONCOLOGY NURSING SESSION</b> Chair: Manuela Eicher, Lausanne, CH	
14:00	<b>Delivery of emergency care for patients with lymphoma in a dedicated facility by advanced nurse practitioners</b> Matt Fowler, Derby, UK	ON1
14:30	<b>CART therapy; spotlight on the role of the nurse</b> Maaïke E.M. de Ruijter, Amsterdam, NL	ON2
15:00	<b>Protocol for a co-design study exploring experiences of lymphoma patients, informal caregivers, and healthcare professionals with CAR-T therapy</b> Margaret McLauchlan, Lausanne, CH	ON3
15:15	<b>The Experience of Patients with Lymphoma and their Informal Caregivers Related To Chimeric Antigen Receptor T-Cell Therapy: A Qualitative Systematic Review</b> Nina Canova, Lausanne, CH	ON4
15:30	<b>Advancing Nursing Knowledge of CD20-CD3 Bispecific Antibody Treatment for B-cell Non-Hodgkin Lymphoma in Australia: A scoping review of adverse events to inform practice</b> Emily Knights, Geelong VIC, AU	ON5

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

15:45	<b>Identifying nursing training needs for the management of bispecific drugs and patient follow-up in onco-hematology units: a non-interventional, e-survey BELL study</b> Juan Parra, Madrid, ES	ON6
16:00	<b>Lymphoma care through patients' eyes: findings from the 2023 Swiss Cancer Patient Experiences (SCAPE) survey</b> Manuela Eicher, Lausanne, CH	ON7
16:15	<b>Educational needs of Swiss patients with hematological diseases: focus on knowledge regarding hematology laboratory results and biomedical concepts</b> Claire Dedieu, Lausanne, CH	ON8
16:30	<b>Living with &amp; beyond Lymphoma: Can End Of Treatment (EOT) Nurse-led clinics bridge the gap?</b> Christina Kirby, Basingstoke, UK	ON9
16:45	<b>Development of a Nurse Specialist Role to an Advanced Nurse Practitioner in Lymphoma Care</b> Heather Watson, Derby, UK	ON10
14:30 – 17:00	<b>Polivalente room, East Campus USI</b> <b>UCL – ICML JOINT SESSION</b> <b>LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE</b> Honorary co-chairs: Jun Ma, Harbin, CN, Jun Zhu, Beijing, CN, Franco Cavalli, Bellinzona, CH, Julie M. Vose, Omaha, NE, US Executive co-chairs: Yubin Song, Beijing, CN, Xiaoqi Li, Shanghai, CN, Davide Rossi, Bellinzona, CH, Laurence L. de Leval, Lausanne, CH	
14:30	Welcome from the co-chairs	
14:35	<b>Advances in DLBCL Management: Highlights from China</b> Donglu Zhao, Harbin, CN	UCL11
14:55	<b>State-of-the-art of Liquid Biopsy in Lymphoma</b> Davide Rossi, Bellinzona, CH	UCL12
15:15	<b>T-cell Lymphoma Treatment: The Chinese Perspective</b> Meng Wu, Beijing, CN	UCL13

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

15:35	BREAK	
15:55	<b>Updates in Radiation Therapies in the Treatment of Lymphoma</b> Lena Specht, Copenhagen, DK	UCL14
16:15	<b>International Overview of Chinese Novel Drugs in Indolent Lymphoma</b> Ou Bai, Changchun, CN	UCL15
16:35	<b>New trends in lymphoma treatment in Western Countries</b> Pier Luigi Zinzani, Bologna, IT	UCL16
16:55	Conclusions remarks by the co-chairs	
15:45 – 16:00	<b>Room A, broadcast in room B, Marquee Parco Ciani, Cinema Corso</b>	<b>Report of the 18-ICML Closed Workshop</b> Riccardo Dalla-Favera, New York, NY, US
16:00 – 17:00	<b>Room A, broadcast in all rooms</b>	<b>SESSION 16: LATE BREAKING ABSTRACTS</b> Co-chairs: Gilles Salles, New York, NY, US and Kim M. Linton, Manchester, UK
16:00	<b>The benefit of Pola-R-CHP in DLBclass-defined molecular subsets of newly diagnosed DLBCL in the POLARIX trial</b> Eleonora Calabretta, Boston, MA, US	LBA1
16:15	<b>Zanubrutinib plus lenalidomide and rituximab versus R-miniCHOP in unfit or frail patients with newly diagnosed diffuse large B-cell lymphoma aged 70 years or older</b> Weili Zhao, Shanghai, CN	LBA2
16:30	<b>Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the Phase III SUNMO trial</b> Jason Westin, Houston, TX, US	LBA3

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------

16:45		<b>Deep Learning-Based Image Analysis of Pretreatment FDG-PET/CT Predicts CAR T-Cell Treatment Outcome at 12 Months</b> Stephen J. Schuster, Philadelphia, PA, US	LBA4
17:45 – 18:45	<b>Room A</b>	<b>THE BIG DEBATE!</b> <b>Ongoing controversies in B-cell lymphoma management</b> Chair: Emanuele Zucca, Bellinzona, CH Satellite symposium organised by the Foundation for the Institute of Oncology Research (IOR) and supported by unrestricted educational grants from AbbVie AG, AstraZeneca AG, BeOne, Eli Lilly and Company, Johnson & Johnson and Roche.	
		<b>DEBATE 1.</b> <b>Should CNS prophylaxis still be offered to DLBCL patients?</b> YES > Andrés J.M. Ferreri, Milan, IT NO > Kate Cwynarski, London, UK	
		<b>DEBATE 2.</b> <b>Which is the best strategy for initial CLL / SLL treatment?</b> Short-term BCL2 targetting > John F. Seymour, Melbourne VIC, AU Continuous BTK inhibition > Stephan Stilgenbauer, Ulm, DE	
		<b>DEBATE 3.</b> <b>Is POLA-R-CHP the new standard for all DLBCL?</b> YES > Sonali M. Smith, Chicago, IL, US NO > Jonathan W. Friedberg, Rochester, NY, US	
19:00 – 21:00	<b>Cinema Corso</b> in-person event only	<b>ESMO-ICML Special Joint Event</b> <b>“Burkitt” documentary film</b> Chair: T. Andrew Lister, London, UK	
		Panel discussion: Martine Chamuleau, Amsterdam, NL, Volker Diehl, Cologne, DE, Éanna Mac Cana, Belfast, UK, Davide Rossi, Bellinzona, CH and Lorna Warwick, Toronto ON, CA	

Tuesday, 17 June	Wednesday, 18 June	Thursday, 19 June	Friday, 20 June	Saturday, 21 June
------------------	--------------------	-------------------	-----------------	-------------------



08:15 – 09:30	<b>Room A, broadcast in Room B</b>	<b>SESSION 17: CNS LYMPHOMAS</b> Co-chairs: Tracy T. Batchelor, Boston, MA, US and Kate Cwynarski, London, UK	
08:15		<b>EFFICACY OF THIOTEPA-CONDITIONED AUTOLOGOUS TRANSPLANTATION IS INDEPENDENT OF RESPONSE TO HD-MTX-BASED INDUCTION IN PRIMARY CNS LYMPHOMA: EBMT SERIES OF 1,545 PATIENTS</b> Teresa Calimeri, Milan, IT	086
08:30		<b>The PRiZM+ Phase II Platform Study for Relapsed and Refractory Primary CNS Lymphoma: First Results from Cohort 1 Zanubrutinib Monotherapy</b> Christopher P. Fox, Nottingham, UK	087
08:45		<b>Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: efficacy and safety from the phase II PROSPECT study</b> Lakshmi Nayak, Boston, MA, US	088
09:00		<b>Tandem CD20-19-Directed Non-Cryopreserved CAR-T Cells–Zamtocabtagene Autoleucel (Zamto-cel) - in Patients with Relapsed/Refractory CNS Lymphoma in DALY II US study</b> Patrick B. Johnston, Rochester, MN, US	089
09:15		<b>Seven-year follow-up of the IELSG42 “MARIETTA” phase II trial: Durable remissions following MATRix/RICE induction and thiotepa autograft in secondary CNS lymphoma</b> Kate Cwynarski, London, UK	090
09:30 – 10:45	<b>Room A</b>	<b>SESSION 18: NEW DRUGS</b> Co-chairs: Anastasios Stathis, Bellinzona, CH and John Kuruvilla, Toronto ON, CA	

09:30		<b>BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) in patients with R/R NHL: Initial Ph 1 results</b> Franck Morschhauser, Lille, FR	091
09:45		<b>E02463 (EO) peptide immunotherapy in combination with lenalidomide (L) and rituximab (R) in patients (pts) with follicular (FL) and marginal zone lymphoma (MZL)</b> Jose C. Villasboas, Rochester, MN, US	092
10:00		<b>Bexobrutideg (NX-5948), a novel BTK degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from ongoing Phase 1a study</b> Alexey Danilov, Duarte, CA, US	093
10:15		<b>Safety and Efficacy of AZD0486, a CD19xCD3 T-cell Engager, in Relapsed or Refractory Diffuse Large B-cell Lymphoma</b> Dai Maruyama, Tokyo, JP	094
10:30		<b>A Phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/ refractory non-Hodgkin lymphoma</b> Lugui Qiu, Tianjin, CN	095
09:45 – 10:45	<b>Room B</b>	<b>“FOCUS ON” SESSION</b> <b>BIOLOGY AND THERAPY OF T-CELL LYMPHOMAS</b> Co-chairs: Pier Luigi Zinzani, Bologna, IT and Zhi-Ming Li, Guangzhou, CN	
09:45		<b>Pluri-omics characterization establishes monomorphic epitheliotropic intestinal T-cell lymphoma and enteropathy associated T-cell lymphoma as two distinct entities</b> David Vallois, Lausanne, CH	162

09:55		<b>Tazemetostat plus Amdizalisib in Relapsed/ Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study</b> Shu Cheng, Shanghai, CN	163
10:05		<b>The Correlation of Mutational Profiles and Valemetostat Efficacy in Patients With R/R PTCL in the Phase 2 VALENTINE-PTCL01 Trial</b> Pier Luigi Zinzani, Bologna, IT	164
10:15		<b>Linperlisib Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma: A Single-Arm, Open-Lable, Multi-Center Phase Ib/II Study (LINCH Trial)</b> Man Nie, Guangzhou, CN	165
10:25		<b>Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Long term follow-up from the TELLOMAK Phase 2 Trial</b> Martine Bagot, Paris, FR	166
10:35		<b>Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with PTCLs after First-line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)</b> Jie Jin, Hangzhou, CN	167
10:45 – 11:15	<b>Room A, broadcast in Room B</b>	<b>18-ICML HIGHLIGHTS “Take Home Messages”</b> Martin Dreyling, Munich, DE	
11:15 – 11:30	<b>Room A, broadcast in Room B</b>	<b>CLOSURE AND FAREWELL</b> Franco Cavalli, Bellinzona, CH	
13:30 – 18:00	<b>Room B</b>	VII EUROPEAN LYMPHOMA CANINE NETWORK WORKSHOP <b>What lies ahead in canine lymphoma therapy?</b> Steering committee: Barbara Rütgen, Vienna, AT, Sabine E. Hammer, Vienna, AT, Hugo Murua-Escobar, Rostock, DE and Peter Vajdovich, Budapest, HU <b>Organised by the European Canine Lymphoma Network</b>	

## Topics of poster presentations

168 – 468

Lymphoma biology	168 – 175
Lymphoma genetics	176 – 190
Lymphoma classification	191 – 196
Lymphoma microenvironment	197 – 207
Chronic lymphocytic leukemia	208 – 220
Follicular Lymphoma	221 – 251
Marginal zone and lymphoplasmacytic lymphoma	252 – 264
Mantle Cell Lymphoma	265 – 276
Aggressive B-cell lymphomas-first line clinical trials	277 – 287
Aggressive B-cell lymphomas outcomes	288 – 315
Relapsed/refractory aggressive B-cell lymphomas: clinical trials	316 – 322
Relapsed/refractory aggressive B-cell lymphomas-real world	323 – 328
CNS Lymphomas	329 – 343
Primary mediastinal lymphoma	344 – 351
Hodgkin Lymphoma	352 – 371
Pediatric lymphomas	372 – 377
PTLD	378 – 381
NK/T-cell Lymphomas	382 – 402
Multiple Myeloma	403 – 407
Imaging and radiomics	408 – 414
Liquid Biopsy	415 – 427
Experimental therapeutics	428 – 435
Novel compounds	436 – 445
CART-cell therapy	446 – 463
New cellular therapies	464 – 468

# TRANSPORT INFORMATION

The Organising Committee promotes the use of public transport with the aim to limit emissions on the territory and avoid unnecessary city traffic. The Organising Committee asks our participants for maximum collaboration and sharing of this project.

Attendees who have booked their accommodation in Ticino can ask for the “Ticino Ticket” upon hotel check-in, a free-of-charge public transport ticket valid for the entire duration of their stay on all public transport in Ticino (buses, trains and postal buses of the “Arcobaleno network”). The Ticino Ticket cannot be purchased: it must be requested upon hotel check-in.

## 18-ICML SHUTTLE SERVICE

A shuttle service connects the Conference locations with the following timetable:  
Tuesday 17, 11:00 - 21:00  
from Wednesday 18 to Friday 20, 07:30 – 21:00  
Please note that, on this service, attendees with physical disabilities have precedence.

Microphones available in the rooms for audience questions will be included in the live streaming of the Conference.

Attendees who would rather not appear on videos and photos are kindly asked to:

## WARNING: RAIL SERVICE INTERRUPTION!

From 21:00 on Saturday 21 June to 08:30 on Sunday 22, due to construction work, rail services in Ticino will be restricted and be replaced by a bus service. For passengers travelling to Milan Malpensa, there will be rail replacement buses between Lugano and Chiasso, and for passengers travelling to Zurich, there will be rail replacement buses between Lugano and Bellinzona. Longer journey times are to be estimated. Please check the online timetable on [www.SBB.ch](http://www.SBB.ch) or in the SBB Mobile App and pay particular attention to the information provided at the train station.

**From the FFS website,  
please note the timetable for Saturday 21  
(updated in May, 2025):**

*last direct ride to Malpensa Airport from Lugano  
FFS Station at 20:06, arrival at 21:41  
last direct ride to Zurich train station HB from  
Lugano FFS Station at 20:30, arrival at 22:27*

**From the FFS website,  
please note the timetable for Sunday 22  
(updated in May, 2025):**

*first direct ride to Malpensa Airport from Lugano  
FFS Station at 09:06, arrival at 10:41  
first direct ride to Zurich train station HB from  
Lugano FFS Station at 08:58, arrival at 10:55*

- send their questions via the Conference platform or App;
  - choose a seat away from the microphones.
- More information is available in 18-ICML Privacy Policy, section C: General Photos and Videos of ICML premises.

## Loading and unloading areas for 18-ICML attendees

Upon request of the Organising Committee, the Lugano City Council has organised three temporary loading and unloading areas for getting to and from the 18-ICML with private services, each at varying distances from the Palazzo dei Congressi.

- Taxis will be allowed to use Piazza Indipendenza, about 1-minute walking distance from the Palazzo dei Congressi, while Via Lucchini will be used as parking area for minivans (up to 12 pax) and NCC (cars with drivers).  
**Parking zone days and times: from Monday 16 to Friday 20, 07:00 - 21:00.  
Saturday 21, 07:00 - 13:00.**

- Larger buses will be able to stop and pick-up attendees on Viale Cattaneo, about 2 minutes walking distance from the Palazzo dei Congressi: a bus lane will be reserved to stop without pre-allocated parking spaces.  
**Parking zone days and times: from Tuesday 17 to Thursday 19, 17:00 - 21:00.  
Friday 20, 17:00 - 20:00.**
- Some hotels are located outside Canton Ticino or are not well-served by timetables that align with the full Conference programme. For transfers to/from these hotels, a space has been reserved inside the Exhibition center, **pavillion MAC 7, (Campo Marzio parking)**, which serves as the designated drop-off/pick-up area.

## FURTHER INFORMATION

Lugano long lake will be closed to traffic on Friday 20 from 20:00.

Thursday 19 is bank holiday in Canton Ticino: shops may be closed and public transportation will run less frequently than on ordinary working days.

## INSURANCE

The Foundation for the Institute of Oncology Research (IOR) bears no responsibility for untoward events in connection with, before, during and after the Conference. Participants are strongly advised to take out their own personal and travel insurance coverage.

## Personal badges must be worn at all times by all participants.

In case of loss of the badge, a fee of CHF 100 will be charged to replace it.

# STRIVING TO ADVANCE BLOOD CANCER CARE

FROM RESEARCH TO REAL LIFE



 **Hematology  
Ambition**  
Advancing science. Elevating care.



**ADVANCING  
SCIENTIFIC  
DISCOVERY**



**PURSuing  
INNOVATIVE  
PARTNERSHIPS**



**OPTIMIZING  
PATIENT  
CARE**

AstraZeneca's Senior Leadership will present an overview of AstraZeneca's commitment to Hematology, current research and pipeline, and will provide a unique opportunity for questions and conversation.

Adverse events should be reported. Reporting forms and information can be found at <https://aereporting.astrazeneca.com>.

This information is intended for healthcare professionals only.

©2024 AstraZeneca. All rights reserved.

PromoMats ID: CH-11334 Date of preparation: 05 2024.

AstraZeneca 